NF1 Clinical Trials 2024

What are the top hospitals conducting nf1 research?

When it comes to clinical trials focused on the treatment and understanding of neurofibromatosis type 1 (NF1), several esteemed hospitals stand out for their significant contributions. At the forefront is the National Institutes of Health Clinical Center in Bethesda, where researchers are currently conducting six active NF1 trials, building upon a remarkable history of 20 previous studies dating back to their initial trial in 2005. In Cincinnati, the Children's Hospital Medical Center has also made substantial strides with five ongoing NF1 trials and an impressive record of 21 completed studies since embarking on their first trial in 2005.

Meanwhile, in Philadelphia, another prominent institution dedicated to pediatric healthcare, the Children's Hospital of Philadelphia, is actively involved in five NF1 trials while having conducted a commendable total of 19 previous investigations since initiating their inaugural trial in 2001. On the West Coast, children diagnosed with NF1 can find solace at Children's Hospital Los Angeles. With four ongoing clinical trials focused on this condition and a track record encompassing thirteen prior studies starting from their first recorded NF1 trial in 2009.

Furthermore contributing towards research endeavors related to NF1 is Children's National Medical Center located within Washington DC where they have four active nf-2 tests while carrying out twenty earlier researched ones after initiating its pioneering investigation into such cases way back until year two thousand two.

These leading hospitals exemplify dedication and innovation as they strive to advance our knowledge about neurofibromatosis type 1 through cutting-edge clinical trials. By joining forces and pushing boundaries within these medical centers across different regions , doctors hope not only to improve treatments but also provide patients affected by this rare genetic disorder with increased comfort along side offering them brighter future prospects ahead

Which are the best cities for nf1 clinical trials?

When it comes to nf1 clinical trials, several cities are at the forefront of research and development. Bethesda, Maryland leads with 13 active trials investigating treatments like Selumetinib and AZD6244. Philadelphia, Pennsylvania follows closely behind with 11 ongoing studies focused on innovative approaches such as Selumetinib granule formulation and Mirdametinib. Los Angeles, California, Chicago, Illinois, and Cincinnati, Ohio also contribute significantly to nf1 research through their respective active trials. These cities offer individuals affected by nf1 access to cutting-edge clinical trials that pave the way for advancements in care and potential breakthroughs in treatment options.

Which are the top treatments for nf1 being explored in clinical trials?

Clinical trials are paving the way for advancements in treating nf1, with several promising treatments leading the charge. Selumetinib takes center stage with its involvement in four active trials and a total of 10 nf1 trials since its introduction in 2010. Joining the ranks is curcumin, high phenolic extra virgin olive oil (HP-EVOO), showing promise in one active trial and one all-time nf1 trial listed as recent as 2022. Additionally, ACT Intervention and FCN-159 demonstrate potential through their participation in one active trial each, contributing to the growing body of research aiming to combat nf1. These ongoing clinical investigations offer hope for improved therapeutic options for patients facing this challenging condition.

What are the most recent clinical trials for nf1?

Recent clinical trials for neurofibromatosis type 1 (NF1) hold promise in advancing treatment options for individuals affected by this condition. One notable trial involves the utilization of a flu and total body irradiation regimen, which has entered phase 2 and became available on May 11, 2023. Additionally, a phase 1 trial exploring the potential benefits of DPCP for NF1 patients was initiated on September 14, 2022. Another phase 1 trial investigated the effects of curcumin and high phenolic extra virgin olive oil as potential therapies for NF1; it became available on July 6, 2022. The development of selumetinib granule formulation is another significant breakthrough in the treatment landscape of NF1; it entered phases 1 and 2 on January21st ,2022 . Lastly,poly ICLC research reached phase two with availability starting from December15th ,202.

What nf1 clinical trials were recently completed?

Recently completed clinical trials in the field of neurofibromatosis type 1 (NF1) have made significant strides towards advancing treatment options for this genetic disorder. These trials address the specific challenges associated with NF1 and aim to improve patient outcomes. Researchers are making notable progress in understanding and targeting the mechanisms underlying NF1, bringing hope to individuals affected by this condition.